13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

NEUROCRINE BIOSCIENCES INC NBIX

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease.
  • Its product candidates in clinical development includes NBI-1076986 to treat movement disorders.
  • The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - specialty & generic?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 25.2 FCF 5.04% Buyback 0.68%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Gotham Asset Management Joel Greenblatt 0.1% $47.4M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 4 13F filing periods
Net reducers 0 Last 4 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $25.2M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +113.6% +191,564 / 168,572
Gotham Asset Management Joel Greenblatt 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 113.6% 13F value change +$23.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 168,572 Last 4 periods +191,564 (+113.6%) Total shares 360,136 Value $47.4M
Soros Fund Management George Soros 2 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$26.5M
13F 2025-06-30 Filed 2025-08-14
Sold out Shares -100.0% 13F value change -$26.5M
Settlement As of 13F 2025-06-30 · Filed 2025-08-14
Base shares 0 Last 4 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.